Raymond James Initiates Coverage On MapLight Therapeutics with Strong Buy Rating, Announces Price Target of $46

MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.

MPLT

0.00

Raymond James analyst Tiago Fauth initiates coverage on MapLight Therapeutics (NASDAQ: MPLT) with a Strong Buy rating and announces Price Target of $46.